Want to see AU:EYE full AI Analyst Report?
EYE Stock Chart & Stats
AU$0.14
>-AU$0.01(-3.23%)
At close: 4:00 PM EDT
AU$0.14
>-AU$0.01(-3.23%)
Day’s Range― - ―
52-Week RangeAU$0.10 - AU$0.21
Previous CloseN/A
Volume91.16K
Average Volume (3M)284.49K
Market Cap
AU$38.46M
Enterprise ValueAU$31.34
Total Cash (Recent Filing)AU$964.00K
Total Debt (Recent Filing)AU$2.39M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Mar 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding284,875,270
10 Day Avg. Volume228,706
30 Day Avg. Volume284,494
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.09
Price to Sales (P/S)0.86
P/FCF Ratio-8.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$42.35M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained revenue expansion indicates stronger commercial reach and product adoption. If maintained, the larger revenue base can improve operating leverage and provide a foundation for the company to move toward profitability.
Gross Margin ImprovementHigher gross margins improve the economics of each sale and create greater capacity to absorb operating costs. The recent margin level supports the durability of the medical-device business model, provided it can be sustained as revenue scales.
Conservative LeverageLow leverage limits interest burden and refinancing exposure, giving Nova Eye more financial flexibility while it develops its business. This balance-sheet strength reduces solvency risk relative to a similarly loss-making company with heavier debt.
Bears Say
Persistent Net LossesDespite improving results, the company has not yet demonstrated sustainable profitability. Continued losses can constrain reinvestment, require external funding, and delay the point at which revenue growth translates into durable shareholder value.
Ongoing Cash BurnPersistent negative cash generation means growth is still consuming funds rather than financing the business internally. Until free cash flow turns positive, Nova Eye may remain dependent on cash reserves or capital raising to support operations and investment.
Shrinking Equity BaseThe falling equity base is consistent with cumulative losses and signals balance-sheet erosion despite low debt. If losses and cash burn persist, reduced equity could weaken financial resilience and increase reliance on future external capital.
Nova Eye Medical News
EYE FAQ
What was Nova Eye Medical’s price range in the past 12 months?
Nova Eye Medical lowest share price was AU$0.10 and its highest was AU$0.20 in the past 12 months.
What is Nova Eye Medical’s market cap?
Nova Eye Medical’s market cap is AU$38.46M.
When is Nova Eye Medical’s upcoming earnings report date?
Nova Eye Medical’s upcoming earnings report date is Mar 02, 2027 which is in 177 days.
How were Nova Eye Medical’s earnings last quarter?
Nova Eye Medical released its earnings results on Aug 26, 2026. The company reported -AU$0.003 earnings per share for the quarter.
Is Nova Eye Medical overvalued?
According to Wall Street analysts Nova Eye Medical’s price is currently Overvalued.
Does Nova Eye Medical pay dividends?
Nova Eye Medical pays a Weekly dividend of AU$0.414 which represents an annual dividend yield of N/A. See more information on Nova Eye Medical dividends here
What is Nova Eye Medical’s EPS estimate?
Nova Eye Medical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nova Eye Medical have?
Nova Eye Medical has 284,875,270 shares outstanding.
What happened to Nova Eye Medical’s price movement after its last earnings report?
Nova Eye Medical reported an EPS of -AU$0.003 in its last earnings report. Following the earnings report the stock price went up 1.429%.
Which hedge fund is a major shareholder of Nova Eye Medical?
Currently, no hedge funds are holding shares in AU:EYE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nova Eye Medical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:EYE Sentiment 93%
Sector Average 60%
Sector Average 60%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
―
20 days / 200 days
Momentum
-86.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.89%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Nova Eye Medical
Nova Eye Medical Limited specializes in the creation, advancement, distribution, marketing, sale, and servicing of surgical equipment dedicated to treating glaucoma. Its diverse product line features iTrack, a surgical system engineered to decrease intraocular pressure (IOP) in adult patients with open-angle glaucoma, and iTrack Advance, an innovative system promoting natural ocular fluid drainage. Furthermore, the company provides Molteno3, a glaucoma drainage device for individuals suffering from severe or intricate forms of the condition, alongside 2RT, a proprietary laser technology employed to address early to intermediate stages of age-related macular degeneration. With a presence spanning Australia, the United States, Europe, the Asia Pacific, and other international markets, the company, originally established in 1985 as Ellex Medical Lasers Limited, officially became Nova Eye Medical Limited in July 2020. Its corporate headquarters are situated in Kent Town, Australia.
Technical Analysis
Cochlear
―
Compumedics Limited
―
Somnomed Limited
―
EMvision Medical Devices Ltd.
―
Control Bionics Ltd.
―